Dermatomyositis and polymyositis (myositis) trials in Argentina
6 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in ArgentinaA Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
- Where
- C.a.b.a, CABA, Capital Federal, La Plata, Quilmes, Rosario, San Miguel de Tucumán, Villa Nueva
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00 - Phase 3Enrolling by invitationA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
- Where
- La Plata, San Miguel, San Miguel de Tucumán
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00 - Phase 3Taking peopleA Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Where
- Buenos Aires, CABA, Ciudad de Buenos Aires, Quilmes, San Miguel de Tucumán
- Age
- 18 years to 75 years
- People
- 240 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06455449 - Phase 3Taking peopleA Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- Where
- Mendoza, Quilmes, SAN M. de Tucuman, Villa Nueva
- Age
- 18 years and over
- People
- 318 worldwide
- Run by
- Pfizer
See details and how to joinNCT05895786 · EU 2022-502739-20-00 - Phase 3Taking peopleA Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- Where
- Mendoza, SAN M. de Tucuman
- Age
- 18 years and over
- People
- 211 worldwide
- Run by
- Pfizer
See details and how to joinNCT06698796 · EU 2024-514648-10-00 - Phase 1Taking peopleA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- Where
- Buenos Aires, San Miguel de Tucumán
- Age
- 18 years to 70 years
- People
- 44 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00